On June 4, Elevance Health rose 3.09% in regular trading, trading at $406.27/share, with trading volume of $93.83 million.
On the news front, Morgan Stanley raised its target price on Elevance Health from $352 to $404, maintaining an equal-weight rating. Earlier, Truist also significantly raised its target price from $375 to $450, maintaining a buy rating. According to FactSet, the stock now carries an average analyst rating of overweight with a mean target price of approximately $406.
The broader Managed Health Care sector rallied in tandem, providing additional tailwinds. Among sector peers, Alignment Healthcare rose 8.14%, Humana rose 6.2%, UnitedHealth rose 5.97%, Centene rose 5.82%, and Molina Healthcare rose 4.37%, reflecting broad-based industry strength.
Elevance Health is a leading U.S. health benefits company operating under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands, serving approximately 45.2 million medical members across multiple states.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments